The estimated Net Worth of Helen M. Thackray is at least $1.87 million dollars as of 14 May 2024. Helen Thackray owns over 30,000 units of GlycoMimetics Inc stock worth over $43,542 and over the last 11 years he sold GLYC stock worth over $524,621. In addition, he makes $1,300,720 as Senior Vice President - Clinical Development et Chief Medical Officer at GlycoMimetics Inc.
Helen has made over 11 trades of the GlycoMimetics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of GLYC stock worth $175,800 on 14 May 2024.
The largest trade he's ever made was buying 30,000 units of GlycoMimetics Inc stock on 14 May 2024 worth over $175,800. On average, Helen trades about 2,392 units every 82 days since 2014. As of 14 May 2024 he still owns at least 272,139 units of GlycoMimetics Inc stock.
You can see the complete history of Helen Thackray stock trades at the bottom of the page.
DR. Helen M. Thackray M.D. serves as Senior Vice President - Clinical Development, Chief Medical Officer of the Company. Dr. Thackray has served as our Senior Vice President of Clinical Development since January 2017 and as our Chief Medical Officer since January 2012 and previously served as our Vice President of Clinical Development from 2006 to January 2017. Prior to joining our company, Dr. Thackray was Vice President of Clinical Product Development at Biosynexus, Inc., a biopharmaceutical company, from 2001 to 2006. From 1995 to 2011, Dr. Thackray was a practicing physician at the Children’s National Medical Center in Washington, D.C., where she also completed her pediatrics residency and served as Pediatric Chief Resident and as an Adjunct Instructor in Pediatrics. From 1999 to 2000, she served as a Medical Genetics Fellow at the National Human Genome Research Institute, part of the National Institutes of Health. Dr. Thackray received a B.S. from Stanford University and an M.D. from The George Washington University School of Medicine. She is a board-certified pediatrician, a Fellow of the American Academy of Pediatrics and Assistant Clinical Professor of Pediatrics at The George Washington University School of Medicine. Dr. Thackray is also a member of the International Conference on Harmonisation E11A Expert Working Group for Pediatric Extrapolation. .
As the Senior Vice President - Clinical Development et Chief Medical Officer of GlycoMimetics Inc, the total compensation of Helen Thackray at GlycoMimetics Inc is $1,300,720. There are 2 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
Helen Thackray is 51, he's been the Senior Vice President - Clinical Development et Chief Medical Officer of GlycoMimetics Inc since 2017. There are 11 older and 3 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
Helen's mailing address filed with the SEC is 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703.
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris et M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
GlycoMimetics Inc executives and other stock owners filed with the SEC include: